AI-Powered microscope could diagnose skin cancer in minutes

NCT ID NCT07682831

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether a machine learning model can accurately diagnose two common types of skin cancer—basal cell carcinoma and squamous cell carcinoma—by analyzing images from a special microscope (two-photon microscopy) that scans skin biopsy samples. The goal is to see if this technology can provide a fast, point-of-care diagnosis that matches the results of standard lab analysis. The study involves 92 adults who are having a skin biopsy for suspected non-melanoma skin cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Two-photon microscopy imaging device
What this could lead to
If successful, this approach could allow doctors to diagnose common skin cancers like basal cell and squamous cell carcinoma quickly and accurately during a clinic visit, without waiting for lab results.
What could go wrong
This is an early-stage study testing a new imaging and AI method. The machine learning model may not yet match the accuracy of standard pathology, and the technology may not be practical for widespread clinic use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA OF SKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Rochester Dermatologic Surgery

    Victor, New York, 14654, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.